search
Back to results

Azithromycin - Ivermectin Mass Drug Administration for Skin Disease (AIM-Skin)

Primary Purpose

Scabies, Yaws, Impetigo

Status
Completed
Phase
Phase 4
Locations
Solomon Islands
Study Type
Interventional
Intervention
Ivermectin
Azithromycin
Permethrin
Sponsored by
London School of Hygiene and Tropical Medicine
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Scabies

Eligibility Criteria

undefined - undefined (Child, Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • All community members are able to be included in the study.

Exclusion Criteria:

  • Allergy to any of the components of the allocated drug regimen

Sites / Locations

  • Atoifi Adventist Hospital

Arms of the Study

Arm 1

Arm 2

Arm Type

Other

Other

Arm Label

Parallel Treatment

Sequential Treatment

Arm Description

Site 1- Parallel Treatment Arm Single dose azithromycin (for yaws) and Ivermectin/Permethrin (for scabies) will be offered on D1. A second dose of Ivermectin/Permethrin will be offered 7-14 days later.

Site 2- Serial Treatment Arm Ivermectin/Permethrin (for scabies) will be offered on D1 with a second dose of Ivermectin/Permethrin offered 7-14 days later.. Single dose azithromycin (for yaws) will be offered at the twelve month follow-up visit.

Outcomes

Primary Outcome Measures

Impetigo Prevalence at 12 Months
Change in prevalence of impetigo between baseline and 12-months

Secondary Outcome Measures

Group A Streptococcus at 12 Months
Change in the percentage of swab samples from which S. pyogenes is cultured between baseline and 12 month follow-up in the two arms
Antimicrobial Resistance in Culture Isolates
The proportion of samples from which a drug-resistant isolate of S.pyogenes is cultured in the two arms

Full Information

First Posted
February 24, 2016
Last Updated
September 13, 2019
Sponsor
London School of Hygiene and Tropical Medicine
Collaborators
Atoifi Adventist Hospital, Solomon Islands, Kirby Institute, Murdoch Childrens Research Institute
search

1. Study Identification

Unique Protocol Identification Number
NCT02775617
Brief Title
Azithromycin - Ivermectin Mass Drug Administration for Skin Disease
Acronym
AIM-Skin
Official Title
Impact of Combined Azithromycin and Ivermectin Mass Drug Administration for Yaws and Scabies - Impact on Impetigo and Skin Microbiology
Study Type
Interventional

2. Study Status

Record Verification Date
September 2019
Overall Recruitment Status
Completed
Study Start Date
July 2016 (Actual)
Primary Completion Date
August 2017 (Actual)
Study Completion Date
February 5, 2018 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
London School of Hygiene and Tropical Medicine
Collaborators
Atoifi Adventist Hospital, Solomon Islands, Kirby Institute, Murdoch Childrens Research Institute

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
This is an open-label prospective community intervention trial to assess the impact of community mass treatment with azithromycin for yaws and ivermectin for scabies, on non-yaws bacterial skin infections. Communities will be randomised to receive standard treatment for both yaws and scabies either in parallel (site 1) or in sequence (site 2). Treatment of yaws: Single dose of Azithromycin (30mg/kg, max 2G). Treatment of scabies: Either an oral dose of Ivermectin (200μg/kg) or permethrin cream for those with a contraindication to Ivermectin (WT<15kg, pregnant or breastfeeding women) given in 2 doses 7-14 days apart. Investigators will complete a clinical and microbiological assessment of bacterial skin disease at baseline and at 12 months to assess the impact of treatment on the prevalence of bacterial infection and the emergence of antimicrobial resistance. Primary Outcome Difference in the change in prevalence of impetigo between baseline and 12- months between the parallel and the sequential treatment arms. Secondary Outcomes Change in the proportion of swab samples from which S. pyogenes is cultured between baseline and follow-up in the two arms The proportion of samples from which a drug-resistant isolate of S.pyogenes is cultured in the two arms

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Scabies, Yaws, Impetigo

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
1291 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Parallel Treatment
Arm Type
Other
Arm Description
Site 1- Parallel Treatment Arm Single dose azithromycin (for yaws) and Ivermectin/Permethrin (for scabies) will be offered on D1. A second dose of Ivermectin/Permethrin will be offered 7-14 days later.
Arm Title
Sequential Treatment
Arm Type
Other
Arm Description
Site 2- Serial Treatment Arm Ivermectin/Permethrin (for scabies) will be offered on D1 with a second dose of Ivermectin/Permethrin offered 7-14 days later.. Single dose azithromycin (for yaws) will be offered at the twelve month follow-up visit.
Intervention Type
Drug
Intervention Name(s)
Ivermectin
Intervention Description
Participants will be offered treatment for both yaws and scabies either in parallel or in sequence. Ivermectin will be offered as a a single dose 200μg/kg on Day 1 and Day 8.
Intervention Type
Drug
Intervention Name(s)
Azithromycin
Intervention Description
Participants will be offered treatment for both yaws and scabies either in parallel or in sequence. Azithromycin will be offered as single dose of 30mg/kg, max 2G.
Intervention Type
Drug
Intervention Name(s)
Permethrin
Intervention Description
Participants will be offered treatment for both yaws and scabies either in parallel or in sequence. Individuals with a contra-indication to ivermectin will be offered Permethrin instead.
Primary Outcome Measure Information:
Title
Impetigo Prevalence at 12 Months
Description
Change in prevalence of impetigo between baseline and 12-months
Time Frame
Baseline and 12 months
Secondary Outcome Measure Information:
Title
Group A Streptococcus at 12 Months
Description
Change in the percentage of swab samples from which S. pyogenes is cultured between baseline and 12 month follow-up in the two arms
Time Frame
12 Months
Title
Antimicrobial Resistance in Culture Isolates
Description
The proportion of samples from which a drug-resistant isolate of S.pyogenes is cultured in the two arms
Time Frame
12 Months

10. Eligibility

Sex
All
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: All community members are able to be included in the study. Exclusion Criteria: Allergy to any of the components of the allocated drug regimen
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Michael Marks
Organizational Affiliation
London School of Hygiene and Tropical Medicine
Official's Role
Principal Investigator
Facility Information:
Facility Name
Atoifi Adventist Hospital
City
Atoifi
State/Province
Malaita
Country
Solomon Islands

12. IPD Sharing Statement

Plan to Share IPD
Undecided
IPD Sharing Plan Description
Anonymised data may be made available
Citations:
PubMed Identifier
29985978
Citation
Marks M, Toloka H, Baker C, Kositz C, Asugeni J, Puiahi E, Asugeni R, Azzopardi K, Diau J, Kaldor JM, Romani L, Redman-MacLaren M, MacLaren D, Solomon AW, Mabey DCW, Steer AC. Randomized Trial of Community Treatment With Azithromycin and Ivermectin Mass Drug Administration for Control of Scabies and Impetigo. Clin Infect Dis. 2019 Mar 5;68(6):927-933. doi: 10.1093/cid/ciy574.
Results Reference
derived

Learn more about this trial

Azithromycin - Ivermectin Mass Drug Administration for Skin Disease

We'll reach out to this number within 24 hrs